Clinical Trial Update: Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating whether low-dose interleukin-2 reduces vascular inflammation in acute coronary syndromes; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• Low-dose Interleukin-2 (interleukin-2)

Snippet

Sponsor: Cambridge University Hospitals NHS Foundation Trust | Conditions: Acute Coronary Syndromes | Phase 2 | Status: COMPLETED